Madrigal Pharmaceuticals, Inc.
MDGL
$579.89
$6.741.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -114.19M | -42.28M | -73.24M | -59.42M | -106.96M |
| Total Depreciation and Amortization | 1.91M | 432.00K | 435.00K | 363.00K | 298.00K |
| Total Amortization of Deferred Charges | 329.00K | 371.00K | 436.00K | 482.00K | 480.00K |
| Total Other Non-Cash Items | 28.70M | 26.10M | 20.93M | 17.73M | 17.44M |
| Change in Net Operating Assets | 163.10M | -31.68M | -37.46M | -63.65M | 21.76M |
| Cash from Operations | 79.85M | -47.05M | -88.89M | -104.49M | -66.98M |
| Capital Expenditure | -857.00K | -- | -- | -195.00K | -779.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -206.14M | 47.86M | 163.88M | -47.76M | -201.61M |
| Cash from Investing | -207.00M | 47.86M | 163.88M | -47.95M | -202.39M |
| Total Debt Issued | 350.00M | -- | -- | -- | -- |
| Total Debt Repaid | -121.66M | -- | -- | -- | -- |
| Issuance of Common Stock | 17.74M | 1.74M | 8.64M | 19.77M | 7.46M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.42M | -- | -- | -- | -- |
| Cash from Financing | 236.65M | 1.74M | 8.64M | 19.77M | 7.46M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 109.50M | 2.55M | 83.63M | -132.67M | -261.91M |